Maternal Self-efficacy and Motor Development in Premature Infants: Clinical Trial Protocol
Launched by UNIVERSIDAD DE LA SABANA · May 14, 2024
Trial Information
Current as of February 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Mothers of a child born prematurely who attend the outpatient kangaroo mother program in Bogotá, Tunja and Zipaquirá in the period between 2024 and 2025.
- • Premature children between 32 to 36.6 weeks who participate in the outpatient kangaroo mother program in Bogotá, Tunja and Zipaquirá in the period between 2024 and 2025.
- Exclusion Criteria:
- • Mothers who manifest any diagnosed mental limitation to participate in the study.
- • Premature children with hemodynamic alterations, congenital malformations, chromosomal syndromes, esophageal atresia, ductus arteriovenosus, heart disease and neurological pathologies.
Trial Officials
Angélica Ospina, PhD
Principal Investigator
Universidad de la Sabana
About Universidad De La Sabana
Universidad de La Sabana is a leading academic institution in Colombia, recognized for its commitment to advancing healthcare research and education. With a strong emphasis on innovation and interdisciplinary collaboration, the university conducts clinical trials aimed at improving patient outcomes and addressing pressing health challenges. Its dedicated research team, equipped with state-of-the-art facilities, adheres to the highest ethical standards and regulatory guidelines, ensuring the integrity and reliability of its studies. Through these efforts, Universidad de La Sabana contributes significantly to the global body of medical knowledge and fosters the development of effective therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0